A randomized trial of bevacizumab for newly diagnosed glioblastoma.

BACKGROUND Concurrent treatment with temozolomide and radiotherapy followed by maintenance temozolomide is the standard of care for patients with newly diagnosed glioblastoma. Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor A, is currently approved for recurrent glioblastoma. Whether the addition of bevacizumab would improve survival among patients with newly diagnosed glioblastoma is not known. METHODS In this randomized, double-blind, placebo-controlled trial, we treated adults who had centrally confirmed glioblastoma with radiotherapy (60 Gy) and daily temozolomide. Treatment with bevacizumab or placebo began during week 4 of radiotherapy and was continued for up to 12 cycles of maintenance chemotherapy. At disease progression, the assigned treatment was revealed, and bevacizumab therapy could be initiated or continued. The trial was designed to detect a 25% reduction in the risk of death and a 30% reduction in the risk of progression or death, the two coprimary end points, with the addition of bevacizumab. RESULTS A total of 978 patients were registered, and 637 underwent randomization. There was no significant difference in the duration of overall survival between the bevacizumab group and the placebo group (median, 15.7 and 16.1 months, respectively; hazard ratio for death in the bevacizumab group, 1.13). Progression-free survival was longer in the bevacizumab group (10.7 months vs. 7.3 months; hazard ratio for progression or death, 0.79). There were modest increases in rates of hypertension, thromboembolic events, intestinal perforation, and neutropenia in the bevacizumab group. Over time, an increased symptom burden, a worse quality of life, and a decline in neurocognitive function were more frequent in the bevacizumab group. CONCLUSIONS First-line use of bevacizumab did not improve overall survival in patients with newly diagnosed glioblastoma. Progression-free survival was prolonged but did not reach the prespecified improvement target. (Funded by the National Cancer Institute; ClinicalTrials.gov number, NCT00884741.).

[1]  K. Hoang-Xuan,et al.  Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.

[2]  Maria Werner-Wasik,et al.  Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  T. Mikkelsen,et al.  Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Susan M. Chang,et al.  Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. , 2012, Neuro-oncology.

[5]  F. Mackenzie,et al.  Diverse roles for VEGF-A in the nervous system , 2012, Development.

[6]  T. Mikkelsen,et al.  Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. , 2011, Neuro-oncology.

[7]  A. Friedman,et al.  The Addition of Bevacizumab to Standard Radiation Therapy and Temozolomide Followed by Bevacizumab, Temozolomide, and Irinotecan for Newly Diagnosed Glioblastoma , 2011, Clinical Cancer Research.

[8]  Paul S Mischel,et al.  Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  A. Sahgal,et al.  Pseudoprogression Following Chemoradiotherapy for Glioblastoma Multiforme , 2010, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[10]  K. Aldape,et al.  A multigene predictor of outcome in glioblastoma. , 2010, Neuro-oncology.

[11]  T. Mikkelsen,et al.  Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  R. Mirimanoff,et al.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.

[13]  John A Butman,et al.  Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  P. Wen,et al.  Response criteria for glioma , 2008, Nature Clinical Practice Oncology.

[15]  M. Delorenzi,et al.  Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma. , 2008, The Journal of molecular diagnostics : JMD.

[16]  A. Gregory Sorensen,et al.  Angiogenesis in brain tumours , 2007, Nature Reviews Neuroscience.

[17]  M. Gilbert,et al.  Validation of the M.D. Anderson Symptom Inventory Brain Tumor Module (MDASI-BT) , 2006, Journal of Neuro-Oncology.

[18]  Napoleone Ferrara,et al.  Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. , 2005, Biochemical and biophysical research communications.

[19]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[20]  R. Jain Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.

[21]  D. Osoba,et al.  The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires , 1996, Quality of Life Research.

[22]  Z L Gokaslan,et al.  A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. , 2001, Journal of neurosurgery.

[23]  P. Kristjansen,et al.  Tumor angiogenesis ‐ a new therapeutic target in gliomas , 1998, Acta neurologica Scandinavica.

[24]  T. Louis,et al.  Statistical analysis of proliferative index data in clinical trials. , 1994, Statistics in medicine.

[25]  H. Müller,et al.  Hazard rate estimation under random censoring with varying kernels and bandwidths. , 1994, Biometrics.

[26]  T. Cascino,et al.  Response criteria for phase II studies of supratentorial malignant glioma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  M Zelen,et al.  The randomization and stratification of patients to clinical trials. , 1974, Journal of chronic diseases.

[28]  D. Cox Regression Models and Life-Tables , 1972 .

[29]  N. Mantel Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[30]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .